Abstract：
UNASSIGNED: Objective: This study aimed to test whether the prognostic value of tryptophanyl-tRNA synthetase 1 (WARS1) for 28-day mortality in patients with sepsis was affected by monocytopenia. Methods: A prospective analysis of retrospectively collected samples from 74 sepsis patients was performed. WARS1, C-reactive protein (CRP), and procalcitonin were measured at admission and 24 and 72 h after admission. The prognostic value of WARS1, CRP, and procalcitonin for 28-day mortality was compared using repeated measures analysis of variance and the area under the receiver operating characteristic curve (AUROC). All analyses were performed in patients with or without monocytopenia, defined as an absolute monocyte count less than 0.1 × 10 9 cells/L. Results: WARS1 levels differed significantly between survivors and nonsurvivors when all patients and patients without monocytopenia were assessed ( P = 0.008, P < 0.001, respectively). In contrast, the WARS1 level did not differ between survivors and nonsurvivors with monocytopenia. C-reactive protein and procalcitonin levels were not different between survivors and nonsurvivors regardless of whether they had monocytopenia. The AUROCs of WARS1 at admission and 24 h for mortality were significantly higher in patients without monocytopenia (0.830, 0.818) than in patients with monocytopenia (0.232, 0.196; P < 0.001, both). When patients without monocytopenia were analyzed, the AUROCs of WARS1 for mortality were 0.830 and 0.818 at admission and 24 h, respectively, which were significantly higher than those of CRP (0.586, 0.653) and procalcitonin (0.456, 0.453) at the same time points ( P = 0.024 and 0.034, respectively). Conclusion: WARS1 is a useful biomarker for prognosis in sepsis patients without monocytopenia.
摘要：
目的：本研究旨在测试色氨酸-tRNA合成酶1（WARS1）对脓毒症患者28天死亡率的预后价值是否受单核细胞减少的影响。
方法：对74例脓毒症患者的回顾性样本进行前瞻性分析。WARS1,C反应蛋白(CRP),在入院时以及入院后24小时和72小时测量降钙素原。WARS1、CRP、使用重复测量方差分析(ANOVA)和受试者工作特征曲线下面积(AUROC)比较28天死亡率和降钙素原.所有分析均在有或没有单核细胞减少症的患者中进行，定义为绝对单核细胞计数小于0.1×109个细胞/L。
结果：当评估所有患者和无单核细胞减少患者时，幸存者和非幸存者之间的WARS1水平存在显著差异（分别为p=0.008，p<0.001）。相比之下,单核细胞减少的幸存者和非幸存者的WARS1水平没有差异.无论是否患有单核细胞减少症，幸存者和非幸存者的CRP和降钙素原水平均无差异。WARS1在入院时和24小时死亡率的AUROC（0.830，0.818）明显高于单核细胞减少患者（0.232，0.196；p<0.001，两者）。当没有单核细胞减少症的患者进行分析时，WARS1对死亡率的AUROC分别为入院时和24小时时的0.830和0.818，分别,显著高于CRP(0.586,0.653)和降钙素原(0.456,0.453)(p分别为0.024和0.034)。
结论：WARS1是无单核细胞减少的脓毒症患者预后的有用生物标志物。
方法：对74例脓毒症患者的回顾性样本进行前瞻性分析。WARS1,C反应蛋白(CRP),在入院时以及入院后24小时和72小时测量降钙素原。WARS1、CRP、使用重复测量方差分析(ANOVA)和受试者工作特征曲线下面积(AUROC)比较28天死亡率和降钙素原.所有分析均在有或没有单核细胞减少症的患者中进行，定义为绝对单核细胞计数小于0.1×109个细胞/L。
结果：当评估所有患者和无单核细胞减少患者时，幸存者和非幸存者之间的WARS1水平存在显著差异（分别为p=0.008，p<0.001）。相比之下,单核细胞减少的幸存者和非幸存者的WARS1水平没有差异.无论是否患有单核细胞减少症，幸存者和非幸存者的CRP和降钙素原水平均无差异。WARS1在入院时和24小时死亡率的AUROC（0.830，0.818）明显高于单核细胞减少患者（0.232，0.196；p<0.001，两者）。当没有单核细胞减少症的患者进行分析时，WARS1对死亡率的AUROC分别为入院时和24小时时的0.830和0.818，分别,显著高于CRP(0.586,0.653)和降钙素原(0.456,0.453)(p分别为0.024和0.034)。
结论：WARS1是无单核细胞减少的脓毒症患者预后的有用生物标志物。
